BE2017C067I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C067I2
BE2017C067I2 BE2017C067C BE2017C067C BE2017C067I2 BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2 BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 C BE2017C067 C BE 2017C067C BE 2017C067 I2 BE2017C067 I2 BE 2017C067I2
Authority
BE
Belgium
Prior art keywords
warm
treatment
allergy
mastocytosis
angioedema
Prior art date
Application number
BE2017C067C
Other languages
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C067(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2017C067I2 publication Critical patent/BE2017C067I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.
BE2017C067C 2003-06-18 2017-12-19 BE2017C067I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives
EP04740016A EP1638574B1 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (1)

Publication Number Publication Date
BE2017C067I2 true BE2017C067I2 (en) 2023-08-09

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C067C BE2017C067I2 (en) 2003-06-18 2017-12-19

Country Status (23)

Country Link
US (2) US8575146B2 (en)
EP (1) EP1638574B1 (en)
JP (2) JP5057780B2 (en)
CN (2) CN101164539A (en)
AT (1) ATE464052T1 (en)
AU (1) AU2004248909B2 (en)
BE (1) BE2017C067I2 (en)
BR (1) BRPI0411563B8 (en)
CA (2) CA2785950A1 (en)
CY (2) CY1110179T1 (en)
DE (1) DE602004026578D1 (en)
DK (1) DK1638574T3 (en)
ES (1) ES2344700T3 (en)
FR (1) FR17C1063I2 (en)
HU (1) HUS000503I2 (en)
LU (1) LUC00055I9 (en)
MX (1) MXPA05013722A (en)
NL (1) NL300917I2 (en)
PL (1) PL1638574T3 (en)
PT (1) PT1638574E (en)
SI (1) SI1638574T1 (en)
TW (1) TWI324604B (en)
WO (1) WO2004112794A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
SI1686997T1 (en) 2003-11-18 2009-08-31 Novartis Ag Inhibitors of the mutant form of kit
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
JP5704785B2 (en) * 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ FLT3 inhibitors for immunosuppression
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN103638028A (en) * 2005-05-02 2014-03-19 诺瓦提斯公司 Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
WO2007010014A2 (en) * 2005-07-20 2007-01-25 Peter Valent Compositions for treatment of systemic mastocytosis
JP5308820B2 (en) * 2005-11-14 2013-10-09 ウニヴェルジテート・チューリッヒ Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
EP2662078A1 (en) 2010-11-10 2013-11-13 National Jewish Health Methods to Treat Allergic Conditions
EP3873462A4 (en) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. METHODS OF TREATMENT OF CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
WO2020097261A1 (en) * 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (en) * 2022-03-15 2025-05-09 국립해양생물자원관 Pharmaceutical composition for preventing or treating nasal polyps comprising streptomyces sp. SNC087 or staurosporine isolated therefrom as an active ingredient

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (en) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE69229490T2 (en) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Medicines containing melatonin
AR004480A1 (en) * 1995-04-06 1998-12-16 Amico Derin C D ASCOMICINE COMPOUNDS HAVING ANTI-INFLAMMATORY ACTIVITY, PROCEDURE TO PREPARE THEM, USE OF SUCH COMPOUNDS TO PREPARE PHARMACEUTICAL AGENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
AU721942B2 (en) * 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
WO1999062537A1 (en) 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
RU2275373C2 (en) * 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Macroheterocyclic compounds
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
DE60227709D1 (en) * 2001-06-29 2008-08-28 Ab Science THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
PT1441737E (en) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
JPWO2004091663A1 (en) 2003-04-18 2006-07-06 協和醗酵工業株式会社 Nerve regeneration drug
EP1637161A4 (en) 2003-04-22 2007-06-27 Astellas Pharma Inc REMEDY FOR NEURODEGENERATIVE BRAIN DISEASES USING PPAR AGONIST [delta]
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
SI1686997T1 (en) 2003-11-18 2009-08-31 Novartis Ag Inhibitors of the mutant form of kit

Also Published As

Publication number Publication date
TWI324604B (en) 2010-05-11
DK1638574T3 (en) 2010-08-02
NL300917I1 (en) 2017-12-12
US8575146B2 (en) 2013-11-05
CN1805749A (en) 2006-07-19
MXPA05013722A (en) 2006-03-08
ES2344700T3 (en) 2010-09-03
JP2006527727A (en) 2006-12-07
FR17C1063I1 (en) 2018-02-16
SI1638574T1 (en) 2010-08-31
JP2012144572A (en) 2012-08-02
CY1110179T1 (en) 2015-01-14
LUC00055I2 (en) 2018-02-21
CA2785950A1 (en) 2004-12-29
WO2004112794A3 (en) 2005-06-16
US20130289018A1 (en) 2013-10-31
US20070299049A1 (en) 2007-12-27
HUS000503I2 (en) 2021-03-29
JP5057780B2 (en) 2012-10-24
CY2017048I2 (en) 2018-09-05
WO2004112794A2 (en) 2004-12-29
PL1638574T3 (en) 2010-09-30
EP1638574A2 (en) 2006-03-29
FR17C1063I2 (en) 2019-05-03
NL300917I2 (en) 2018-01-09
CN101164539A (en) 2008-04-23
TW200512213A (en) 2005-04-01
BRPI0411563B1 (en) 2019-09-24
DE602004026578D1 (en) 2010-05-27
PT1638574E (en) 2010-07-14
LUC00055I9 (en) 2022-11-09
CA2527703A1 (en) 2004-12-29
AU2004248909A1 (en) 2004-12-29
EP1638574B1 (en) 2010-04-14
CN100457111C (en) 2009-02-04
ATE464052T1 (en) 2010-04-15
CA2527703C (en) 2012-10-23
HUS1700053I1 (en) 2018-01-29
CY2017048I1 (en) 2018-09-05
HK1095519A1 (en) 2007-05-11
AU2004248909B2 (en) 2008-05-08
BRPI0411563A (en) 2006-08-01
LUC00055I1 (en) 2017-12-14
BRPI0411563B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
FR17C1063I1 (en)
DK1611088T3 (en) Hydroxymates as therapeutic agents
WO2003066579A3 (en) Novel bicyclic hydroxamates as inhibitors of histone deacetylase
EA200971053A1 (en) METHODS OF TREATMENT OF THE LEAD ULCERS
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201390353A1 (en) DERIVATIVE PYRAZOLOHINOLINA
EP1539234A4 (en) METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
ATE520668T1 (en) SIGMARECEPTOR INHIBITORS
PL1656348T3 (en) Acetylene derivatives as inhibitors of histone deacetylase
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
GB2427405A (en) Novel hydroxamates as therapeutic agents
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
TH401002069A (en) New uses of the sternosporine derivative
SE0103539D0 (en) New Use